Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: Results of a prospective randomized multicenter clinical trial

S. Yanovich, P. Mitsky, Kenneth Cornetta, R. T. Maziarz, C. Rosenfeld, D. S. Krause, J. P. Lotz, J. D. Bitran, S. Williams, R. Preti, G. Somlo, B. Burtness, B. Mills

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Tumor contamination of autologous peripheral blood stem/progenitor cell grafts occurs in a substantial proportion of high-risk breast cancer patients, and the possibility that such contamination may contribute to relapse has focused attention on methods for removal of the contaminating cells prior to transplantation. One such approach is positive selection of CD34+ cells. A fully automated immunomagnetic cell selection system has recently been introduced to facilitate the positive selection process. A multicenter randomized clinical trial was designed to evaluate the capacity of CD34+ cells isolated using the fully automated system to support prompt hematopoietic reconstitution following high-dose chemotherapy in high-risk breast cancer patients, as well as to assess the safety and tolerability of the CD34+ cell transplants. In recipients of isolated CD34+ cells, the median time to an absolute neutrophil count ≥ 500/μl was 10 days, a value identical to that observed in patients receiving unfractionated apheresis collections. In the isolated CD34+ cell recipients median time to a platelet count ≥ 20,000/μl was 12 days, compared with 10 days in the unfractionated cell group. There were no statistically significant differences between the groups in median time to neutrophil or platelet engraftment. Infusion of autologous cells was well tolerated by the study groups. There were no intergroup differences in the incidence of infections, need for platelet transfusions, or duration of hospitalization. Isolated CD34+ cells were high in purity and sufficient in number for use in autologous transplantation. The fully automated immunomagnetic cell selection system affords an efficient and time-saving option for isolation of CD34+ cells to be used as autologous grafts in highrisk breast cancer patients, and the isolated CD34+ cells support undelayed hematopoietic reconstitution.

Original languageEnglish
Pages (from-to)1165-1174
Number of pages10
JournalBone Marrow Transplantation
Volume25
Issue number11
StatePublished - 2000

Fingerprint

Multicenter Studies
Blood Cells
Randomized Controlled Trials
Transplantation
Breast Neoplasms
Transplants
Neutrophils
Platelet Transfusion
Blood Component Removal
Cell Separation
Autologous Transplantation
Platelet Count
Hospitalization
Stem Cells
Blood Platelets
Safety
Recurrence
Drug Therapy
Incidence
Infection

Keywords

  • Antigens
  • Breast neoplasms
  • CD34
  • Controlled clinical trials
  • Hematopoietic stem cell transplantation
  • Immunomagnetic separation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer : Results of a prospective randomized multicenter clinical trial. / Yanovich, S.; Mitsky, P.; Cornetta, Kenneth; Maziarz, R. T.; Rosenfeld, C.; Krause, D. S.; Lotz, J. P.; Bitran, J. D.; Williams, S.; Preti, R.; Somlo, G.; Burtness, B.; Mills, B.

In: Bone Marrow Transplantation, Vol. 25, No. 11, 2000, p. 1165-1174.

Research output: Contribution to journalArticle

Yanovich, S, Mitsky, P, Cornetta, K, Maziarz, RT, Rosenfeld, C, Krause, DS, Lotz, JP, Bitran, JD, Williams, S, Preti, R, Somlo, G, Burtness, B & Mills, B 2000, 'Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: Results of a prospective randomized multicenter clinical trial', Bone Marrow Transplantation, vol. 25, no. 11, pp. 1165-1174.
Yanovich, S. ; Mitsky, P. ; Cornetta, Kenneth ; Maziarz, R. T. ; Rosenfeld, C. ; Krause, D. S. ; Lotz, J. P. ; Bitran, J. D. ; Williams, S. ; Preti, R. ; Somlo, G. ; Burtness, B. ; Mills, B. / Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer : Results of a prospective randomized multicenter clinical trial. In: Bone Marrow Transplantation. 2000 ; Vol. 25, No. 11. pp. 1165-1174.
@article{805b0fc1f15744819c84c077bbb9d119,
title = "Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: Results of a prospective randomized multicenter clinical trial",
abstract = "Tumor contamination of autologous peripheral blood stem/progenitor cell grafts occurs in a substantial proportion of high-risk breast cancer patients, and the possibility that such contamination may contribute to relapse has focused attention on methods for removal of the contaminating cells prior to transplantation. One such approach is positive selection of CD34+ cells. A fully automated immunomagnetic cell selection system has recently been introduced to facilitate the positive selection process. A multicenter randomized clinical trial was designed to evaluate the capacity of CD34+ cells isolated using the fully automated system to support prompt hematopoietic reconstitution following high-dose chemotherapy in high-risk breast cancer patients, as well as to assess the safety and tolerability of the CD34+ cell transplants. In recipients of isolated CD34+ cells, the median time to an absolute neutrophil count ≥ 500/μl was 10 days, a value identical to that observed in patients receiving unfractionated apheresis collections. In the isolated CD34+ cell recipients median time to a platelet count ≥ 20,000/μl was 12 days, compared with 10 days in the unfractionated cell group. There were no statistically significant differences between the groups in median time to neutrophil or platelet engraftment. Infusion of autologous cells was well tolerated by the study groups. There were no intergroup differences in the incidence of infections, need for platelet transfusions, or duration of hospitalization. Isolated CD34+ cells were high in purity and sufficient in number for use in autologous transplantation. The fully automated immunomagnetic cell selection system affords an efficient and time-saving option for isolation of CD34+ cells to be used as autologous grafts in highrisk breast cancer patients, and the isolated CD34+ cells support undelayed hematopoietic reconstitution.",
keywords = "Antigens, Breast neoplasms, CD34, Controlled clinical trials, Hematopoietic stem cell transplantation, Immunomagnetic separation",
author = "S. Yanovich and P. Mitsky and Kenneth Cornetta and Maziarz, {R. T.} and C. Rosenfeld and Krause, {D. S.} and Lotz, {J. P.} and Bitran, {J. D.} and S. Williams and R. Preti and G. Somlo and B. Burtness and B. Mills",
year = "2000",
language = "English",
volume = "25",
pages = "1165--1174",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer

T2 - Results of a prospective randomized multicenter clinical trial

AU - Yanovich, S.

AU - Mitsky, P.

AU - Cornetta, Kenneth

AU - Maziarz, R. T.

AU - Rosenfeld, C.

AU - Krause, D. S.

AU - Lotz, J. P.

AU - Bitran, J. D.

AU - Williams, S.

AU - Preti, R.

AU - Somlo, G.

AU - Burtness, B.

AU - Mills, B.

PY - 2000

Y1 - 2000

N2 - Tumor contamination of autologous peripheral blood stem/progenitor cell grafts occurs in a substantial proportion of high-risk breast cancer patients, and the possibility that such contamination may contribute to relapse has focused attention on methods for removal of the contaminating cells prior to transplantation. One such approach is positive selection of CD34+ cells. A fully automated immunomagnetic cell selection system has recently been introduced to facilitate the positive selection process. A multicenter randomized clinical trial was designed to evaluate the capacity of CD34+ cells isolated using the fully automated system to support prompt hematopoietic reconstitution following high-dose chemotherapy in high-risk breast cancer patients, as well as to assess the safety and tolerability of the CD34+ cell transplants. In recipients of isolated CD34+ cells, the median time to an absolute neutrophil count ≥ 500/μl was 10 days, a value identical to that observed in patients receiving unfractionated apheresis collections. In the isolated CD34+ cell recipients median time to a platelet count ≥ 20,000/μl was 12 days, compared with 10 days in the unfractionated cell group. There were no statistically significant differences between the groups in median time to neutrophil or platelet engraftment. Infusion of autologous cells was well tolerated by the study groups. There were no intergroup differences in the incidence of infections, need for platelet transfusions, or duration of hospitalization. Isolated CD34+ cells were high in purity and sufficient in number for use in autologous transplantation. The fully automated immunomagnetic cell selection system affords an efficient and time-saving option for isolation of CD34+ cells to be used as autologous grafts in highrisk breast cancer patients, and the isolated CD34+ cells support undelayed hematopoietic reconstitution.

AB - Tumor contamination of autologous peripheral blood stem/progenitor cell grafts occurs in a substantial proportion of high-risk breast cancer patients, and the possibility that such contamination may contribute to relapse has focused attention on methods for removal of the contaminating cells prior to transplantation. One such approach is positive selection of CD34+ cells. A fully automated immunomagnetic cell selection system has recently been introduced to facilitate the positive selection process. A multicenter randomized clinical trial was designed to evaluate the capacity of CD34+ cells isolated using the fully automated system to support prompt hematopoietic reconstitution following high-dose chemotherapy in high-risk breast cancer patients, as well as to assess the safety and tolerability of the CD34+ cell transplants. In recipients of isolated CD34+ cells, the median time to an absolute neutrophil count ≥ 500/μl was 10 days, a value identical to that observed in patients receiving unfractionated apheresis collections. In the isolated CD34+ cell recipients median time to a platelet count ≥ 20,000/μl was 12 days, compared with 10 days in the unfractionated cell group. There were no statistically significant differences between the groups in median time to neutrophil or platelet engraftment. Infusion of autologous cells was well tolerated by the study groups. There were no intergroup differences in the incidence of infections, need for platelet transfusions, or duration of hospitalization. Isolated CD34+ cells were high in purity and sufficient in number for use in autologous transplantation. The fully automated immunomagnetic cell selection system affords an efficient and time-saving option for isolation of CD34+ cells to be used as autologous grafts in highrisk breast cancer patients, and the isolated CD34+ cells support undelayed hematopoietic reconstitution.

KW - Antigens

KW - Breast neoplasms

KW - CD34

KW - Controlled clinical trials

KW - Hematopoietic stem cell transplantation

KW - Immunomagnetic separation

UR - http://www.scopus.com/inward/record.url?scp=0034129270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034129270&partnerID=8YFLogxK

M3 - Article

C2 - 10849529

AN - SCOPUS:0034129270

VL - 25

SP - 1165

EP - 1174

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -